Main Article Content
atopic dermatitis, prevalence, pathogenesis, economical-social burden, diagnosis, treatment
Atopic dermatitis (AD) is a common inflammatory skin disease, clinically characterized by recurrent eczematous lesions and intense itching, leading to excoriations and susceptibility to cutaneous infections. Although it is considered a pediatric disorder, mainly starting in infancy, it is also very common in adults. Etiology of AD is complex and multifactorial: interaction between genetic susceptibility and environment, but also cutaneous barrier impairment, change in microbiome composition and innate and adaptive immune dysregulation are the main factors involved in the pathogenesis of the disease. Originally, the disorder was considered mediated by an imbalance towards a T-helper 2 response and excessive IgE production to allergens, but now it is recognized as a lifelong disposition with variable clinical expressivity, where dysfunctions of the epidermal barrier, immune system and microbiome play a central role. AD leads to a substantial psycho-social burden on patients and their relatives and increases the risk of other allergic and non allergic disorders. The real economic impact of AD is difficult to measure due to the broad spectrum of disease severity and the multiple direct and indirect costs, but the overall medical expenses seem to be very high and similar to those of other diseases such as diabetes. Currently, a multiple therapeutic approach is aimed only at improving the skin state, reducing itching and keeping a stable condition. New safety and curative treatments may be developed only after enhancing our understanding on the pathogenesis of AD and the heterogeneity of its clinical manifestations.
2.Meglio M, Maiello N, Galli E. Atopic Dermatitis ERS Handbook: Paediatric Respiratory Medicine 2012.
3.Patrick M, Brunner, Donald YM, Leung M, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic Dermatitis. Ann Allergy Asthma Immunol 2018;120:34-41.
4.Kusari A, Han AM, Schairer D, Eichenfield LF. Atopic dermatitis: new developments. Dermatol Clin 2019; 37:11-20.
5.De la O-Escamilla NO, Sidbury R. Atopic dermatitis: update on pathogenesis and therapy. Pediatr Ann 2020;49:e140-e146.
6.Abuabara K, Yu AM, Okhovat JP, Allen IE, Langan SM. The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies. Allergy 2018;73: 696-704.
7.Cabanillas B, Brehler AC, Novak N. Atopic dermatitis phenotypes and the need for personalized medicine. Curr Opin Allergy Clin Immunol 2017;17:309-315.
8.Cantarutti A, Donà D, Visentin F, Borgia E, Scamarcia A, Cantarutti L. epidemiology of frequently occurring skin diseases in italian children from 2006 to 2012: a retrospective, population-based study. Pediatr Dermatol 2015;32:668-78.
9.Lopez Carrera YI, Al Hammadi A, Huang YH, Llamado LJ, Mahgoub E, Tallman AM. Epidemiology, Diagnosis, and treatment of atopic dermatitis in the developing countries of Asia, Africa, Latin America, and the Middle East: a review. Dermatol Ther (Heidelb) 2019;9:685-705.
10.Kowalska-Olędzka E, Czarnecka M, Baran A. Epidemiology of atopic dermatitis in Europe. J Drug Assess 2019;8:126-128.
11.Silverber JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin 2017;35: 283–289.
12.Deckers IAG, McLean S, Linssen S, Mommers M, van Schayck CP, SheiKh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. PloS one 2012;7:e39803.
13.Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol 2019;122:449-455.
14.Brunner PM. Early immunologic changes during the onset of atopic dermatitis. Ann Allergy Asthma Immunol 2019;123:152-157.
15.Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. skin barrier abnormalities and immune dysfunction in atopic dermatitis. Int J Mol Sci 2020;21:2867.
16.Elias PM. Primary role of barrier dysfunction in the pathogenesis of atopic dermatitis. Exp Dermatol 2018; 27: 847-851.
17.Nakatsuji T, Gallo RL. The role of the skin microbiome in atopic dermatitis. Ann Allergy Asthma Immunol 2019;122:263-269.
18.Danby SG, Cork MJ. pH in atopic dermatitis. Curr Probl Dermatol 2018;54:95-107.
19.Berdyshev E, Goleva E, Bronova I, et al. Lipid abnormalities in atopic skin are driven by type 2 cytokines. JCI Insight 2018;3: e98006.
20.Tham EH, Leung DY. Mechanisms by which atopic dermatitis predisposes to food allergy and the atopic march. Allergy Asthma Immunol Res 2019;11:4-15.
21.Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol 2020;124:36-43.
22.Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441-6.
23.Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: End of the drought? J Allergy Clin Immunol 2017;140:633-643.
24.Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis. J Allergy Clin Immunol 2019;143:26-35.
25.Baviera G, Maiello N, Galli E. Staphylococcus Aureus and atopic dermatitis: which came first, the chicken or the egg? EMJ Dermatol 2015;3:92-97.
26.Leung DYM. The microbiome and allergic diseases: a struggle between good and bad microbes. Ann Allergy Asthma Immunol 2019;122:231-232.
27.Glatz M, Jo JH, Kennedy EA, et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLoS One 2018;13:e0192443.
28.Ciaccio CE. Modulating the microbiome: The future of allergy therapeutics? Ann Allergy Asthma Immunol 2019;122:233-235.
29.Yang TB, Kim BS. Pruritus in allergy and immunology. J Allergy Clin Immunol 2019;144:353-360.
30.Harrison IP, Spada F. Breaking the itch-scratch cycle: topical options for the management of chronic cutaneous itch in atopic dermatitis. Medicines (Basel) 2019;6:76.
31.Galli E, Neri I, Ricci G, et al. Consensus conference on clinical management of pediatric atopic dermatitis. Ital J Pediatr 2016;42:26.
32. Silverberg NB. Pediatric molluscum: an update. Cutis 2019;104:301-305;E1;E2.
33.Nowicka D, Nawrot U. Contribution of Malassezia spp. to the development of atopic dermatitis. Mycoses 2019;62:588-596.
34.Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract 2020;8:91-101.
35. Stalder JF, Taïeb A, Atherton DJ, et al. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31.
36.Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11-8.
37.Coutanceau C, Stalder JF.Analysis of correlations between patient-oriented SCORAD (PO-SCORAD) and other assessment scores of atopic dermatitis severity and quality of life. Dermatology 2014;229:248-55.
38.Tham EH, Leung DY. Mechanisms by which atopic dermatitis predisposes to food allergy and the atopic march. Allergy Asthma Immunol Res 2019;11:4-15.
39. Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol 2018;120:131-137.
40. Aw M, Penn J, Gauvreau GM, Lima H, Sehmi R. Atopic march: Collegium Internationale Allergologicum Update 2020. Int Arch Allergy Immunol 2020;181:1-10.
41.Khan SJ, Dharmage SC, Matheson MC, Gurrin LC. Is the atopic march related to confounding by genetics and early-life environment? A systematic review of sibship and twin data. Allergy 2018; 73:17-28.
42.Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Councilors of the international Eczema Council. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest.Dermatol 2017;137:18-25.
43.Cipriani F, Ricci G, Leoni MC, et al. Autoimmunity in atopic dermatitis: Biomarker or simply epiphenomenon? J Dermatol 2014;41:569–576.
44.Oliveira C, Torres T. More than skin deep: the systemic nature of atopic dermatitis. Eur J Dermatol 2019;29:250-258.
45. Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol 2019;123:144-151.
46. Johansson EK, Ballardini N, Kull I, Bergstrṏm A, Wahlgren CF. Association between preschool eczema and medication for attention-deficit/hyperactivity disorder in school age. Pediatr Allergy Immunol 2017;28:44–50.
47.Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol 2017;137:26-30.
48.Bickers DR, Lim HW, Margolis D, et al. American Academy of Dermatology Association; Society for Investigative Dermatology. The burden of the skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigation Dermatology. J Am Acad Dermatol 2006;55:490-500.
49.Narla S, Hsu DY, Thyssen JP, Silverberg JI. Inpatient financial burden of atopic dermatitis in the United States. J Invest Dermatol 2017;137:1461-1467.
50.Chung J, Simpson EL. The socioeconomics of atopic dermatitis. Ann Allergy Asthma Immunol 2019;122:360-360.
51.Koszorú K, Borza J, Gulácsi L, Sárdy M. Quality of life in patients with atopic dermatitis. Cutis 2019;104:174-177.
52.Ring J, Zink A, Arents BWM, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol 2019;33:1331-1340.
53.Jarosz M, Syed S, Błachut M, Badura Brzoza K. Emotional distress and quality of life in allergic diseases. Wiad Lek 2020;73:370-373.
54.Xu X, Van Galen LS, Koh MJA, et al. Factors influencing quality of life in children with atopic dermatitis and their caregivers: a cross-sectional study. Sci Rep 2019; 9: 15990.
55.Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injures in 21 regions 1990-2010: A systematic analysis for the Global Burden of Disease study 2010. Lancet 2012;380:2197-223.
56.Katoh N, Ohya Y, Ikeda M, et al. Japanese guidelines for atopic dermatitis 2020. Allergol Int 2020; S1323-8930(20)30018-6.
57.Chiricozzi A, Belloni Fortina A, Galli E, et al. Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel. Allergol Immunopathol (Madr) 2019;47: 194-206.
58. Mastrorilli C, Caffarelli C. Hoffmann-Sommergruber K. Food allergy and atopic dermatitis: Prediction, progression, and prevention.Pediatr Allergy Immunol. 2017;28:831–840.
59. Galli E, Carello R, Fantò M, Maiello N. Lo skin care nel bambino con dermatite atopica. In Ugazio AG, Marseglia GL: Immunologia e allergologia pediatrica. p.598-605 Pacini Editore Medicina 2019.
59.Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatol 2017;153:1036-1042.
60.Cury Martins J, Martins C, Aoki V, Gois AFT, Ishii Ha, Da Silva EMK. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015;(7):CD009864.
61.Lee SE, Choi Y, Kim SE, Noh EB,Kim SC. Differential effects of topical corticosteroid and calcineurin inhibitor on the epidermal tight junction. Exp Dermatol 2013;22:59-61.
62.Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimond D,Bilker WB. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol 2015;151:594-9.
63. Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol 2017;77:623-633.
64.Drucker AM, Eyerich K, De Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol 2018;178:768-775.
65.Carboni E, Galli E, Anastasio E. La nuova frontiera terapeutica della dermatite atopica. Riv Immunol Allergol Pediatrica 2019;3:35-40.
66.Deleanu D, Nedelea I. Biological therapies for atopic dermatitis: An update. Exp Ther Med 2019 ;17:1061-1067.
67.Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2020;82:377-388.